Explore the latest news, breakthroughs, and updates from our team. Stay informed about our ongoing research, upcoming clinical trials, and the significant impact we’re making in the field of biotechnology.
We are proud to announce that our Chief Scientific Officer, Dr. Johannes Karges, has received the prestigious Paul Ehrlich and Ludwig Darmstaedter Early Career Prize for his groundbreaking invention of our innovative chemotherapy approach. This esteemed award is one of the most highly endowed and internationally recognized honors in the field of medicine in Germany, with many past recipients going on to become Nobel Prize winners.
NUP-CTx at 2025 Seed Showcase in San Francisco, CA
We are excited to announce that NUP-CTx Inc. has been selected to present at the 2025 Seed Showcase, which will take place during the Biotech Showcase in San Francisco from January 13-15. This prestigious event brings together key players in the biotech industry, and we are honored to share our novel approach to chemotherapy.
More information can be found at https://informaconnect.com/biotech-showcase/
Published on October 24, 2024
NUP-CTx Presents at BioFuture 2024 in New York
We are proud to announce that NUP-CTx Inc. has been selected to present our new chemotherapy approach at BioFuture 2024 in New York (October 2024).
More information can be found at https://biofuture.com/
Published on October 24, 2024
Second International Patent Filed
We are excited to announce the filing of our second international patent, titled “Polymeric prodrug nanoparticles for tumor-targeted ultrasound-activated cancer therapy”, securing further protection for our novel technology.
Published on October 18, 2024
Bio Investor Forum at the Fairmont San Francisco, CA
We are pleased to announce that NUP-CTx Inc. will be featured at the Bio Investor Forum on October 15-16 at the Fairmont San Francisco, CA. This exciting event offers a fantastic opportunity to engage with our team and discover more about our innovative chemotherapy approaches.
More information can be found at https://bif.bio.org/
Published on September 30, 2024
Several Patents with Worldwide Protection Pending
Our first patent, “Prodrug Nanoparticle for Tumor-Targeted Ultrasound-Activated Cancer Therapy,” has already been registered (European patent application; official application number 24183965.3).
Published on September 26, 2024